AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11053705 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone
Number of subjects: 150
Study 8881091 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure therapy
Number of subjects: 28
Study 8881091 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive restructuring
Number of subjects: 28
Study 1733879 — intervention group
Group type: EXPERIMENTAL
Intervention: Ionic high‐osmolar contrast medium
Number of subjects: 100
Study 1733879 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonionic low‐osmolar contrast medium
Number of subjects: 100
Study 2861630 — intervention group
Group type: EXPERIMENTAL
Intervention: Broxaterol 0.250 mg
Number of subjects: 10
Study 2861630 — intervention group
Group type: EXPERIMENTAL
Intervention: Broxaterol 0.500 mg
Number of subjects: 10
Study 2861630 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol 4 mg
Number of subjects: 10
Study 27485140 — intervention group
Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 0
Study 26873712 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% ASiR
Number of subjects: 40
Study 26873712 — intervention group
Group type: COMPARATOR
Intervention: 30% ASiR
Number of subjects: 40
Study 25025755 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib 300 mg BID
Number of subjects: 593
Study 25025755 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib 400 mg BID
Number of subjects: 593
Study 25025755 — intervention group
Group type: COMPARATOR
Intervention: Imatinib 400 mg daily
Number of subjects: 593
Study 23063390 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction osteogenesis with 0.5-mm distraction applied twice a day (1 mm/d) for 5 mm lengthening followed by 4 weeks consolidation
Number of subjects: 21
Study 23063390 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction osteogenesis with 0.5-mm distraction applied twice a day (1 mm/d) for 5 mm lengthening followed by 8 weeks consolidation
Number of subjects: 21
Study 23063390 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction osteogenesis with 0.5-mm distraction applied twice a day (1 mm/d) for 5 mm lengthening followed by 12 weeks consolidation
Number of subjects: 21
Study 23063390 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonoperated hemimandibles of 6 rabbits)
Number of subjects: 21
Study 20408074 — intervention group
Group type: EXPERIMENTAL
Intervention: Combigan drops (brimonidine 0.2 % and timolol 0.5 %)
Number of subjects: 88
Study 20408074 — intervention group
Group type: COMPARATOR
Intervention: Placebo drops (artificial tears)
Number of subjects: 88
Study 18987758 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydration alone
Number of subjects: 412
Study 18987758 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydration plus one-time hemodialysis
Number of subjects: 412
Study 18987758 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydration plus N-acetylcysteine
Number of subjects: 412
Study 16429868 — intervention group
Group type: EXPERIMENTAL
Intervention: SmartClip brackets
Number of subjects: 58
Study 16429868 — intervention group
Group type: COMPARATOR
Intervention: Conventional twin brackets
Number of subjects: 58
Study 11293556 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg
Number of subjects: 418
Study 11293556 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocodone 10 mg/acetaminophen 1000 mg
Number of subjects: 418
Study 11293556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 418
Study 10078088 — intervention group
Group type: EXPERIMENTAL
Intervention: cilazapril 1 mg daily
Number of subjects: 367
Study 10078088 — intervention group
Group type: EXPERIMENTAL
Intervention: captopril 25 mg three times daily
Number of subjects: 367
Study 10078088 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 367
Study 8077542 — intervention group
Group type: EXPERIMENTAL
Intervention: QRS + 100 shock (delivered 100 ms after QRS onset)
Number of subjects: 15
Study 8077542 — intervention group
Group type: COMPARATOR
Intervention: QRS + 0 shock (delivered at QRS onset)
Number of subjects: 15
Study 2582725 — intervention group
Group type: EXPERIMENTAL
Intervention: Ouabain (Na+/K+ ATPase inhibitor)
Number of subjects: 0
Study 2582725 — intervention group
Group type: COMPARATOR
Intervention: Phentolamine (alpha-adrenoceptor antagonist)
Number of subjects: 0
Study 2582725 — intervention group
Group type: COMPARATOR
Intervention: Bretylium tosylate (neurotransmitter blocker)
Number of subjects: 0
Study 2582725 — intervention group
Group type: COMPARATOR
Intervention: Histamine (vasodilator)
Number of subjects: 0
Study 2582725 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenaline (postsynaptic vascular alpha-adrenoceptor stimulator)
Number of subjects: 0
Study 4361353 — intervention group
Group type: EXPERIMENTAL
Intervention: CP‐20,961 (interferon inducer)
Number of subjects: 29
Study 4361353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 4361353 — intervention group
Group type: EXPERIMENTAL
Intervention: CP‐20,961
Number of subjects: 29
Study 30834725 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri, salivarius and acidophilus
Number of subjects: 60
Study 30834725 — intervention group
Group type: COMPARATOR
Intervention: Placebo with xylitol
Number of subjects: 60
Study 28267039 — intervention group
Group type: EXPERIMENTAL
Intervention: Baroreceptor-activating therapy (BAT)
Number of subjects: 16
Study 28267039 — intervention group
Group type: COMPARATOR
Intervention: Control (BAT off)
Number of subjects: 16
Study 26931635 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral weight loss intervention
Number of subjects: 227
Study 26931635 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 227
Study 24727325 — intervention group
Group type: EXPERIMENTAL
Intervention: LCS6 G-allele carriers (n = 432 blood samples, n = 143 tumor samples)
Number of subjects: 2834
Study 24727325 — intervention group
Group type: COMPARATOR
Intervention: LCS6 T-allele carriers (n = 2,402 blood samples, n = 834 tumor samples)
Number of subjects: 2834
Study 22012877 — intervention group
Group type: EXPERIMENTAL
Intervention: High-speed power training (HSPT)
Number of subjects: 33
Study 22012877 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-speed strength training (SSST)
Number of subjects: 33
Study 22012877 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 33
Study 19946241 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/daily for 2 months and 10 mg for the next 4 months
Number of subjects: 68
Study 19946241 — intervention group
Group type: COMPARATOR
Intervention: Control group (no statin therapy)
Number of subjects: 68
Study 17185309 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate non-manual occupations
Number of subjects: 6999
Study 17185309 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower officials and foremen
Number of subjects: 6999
Study 17185309 — intervention group
Group type: EXPERIMENTAL
Intervention: Semiskilled and skilled workers
Number of subjects: 6999
Study 17185309 — intervention group
Group type: EXPERIMENTAL
Intervention: Unskilled workers
Number of subjects: 6999
Study 17185309 — intervention group
Group type: EXPERIMENTAL
Intervention: Men with a principal diagnosis of HF (n=516)
Number of subjects: 6999
Study 11561740 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 100 mcg every 6 hours
Number of subjects: 58
Study 11561740 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol 50 mcg every 4 hours
Number of subjects: 58
Study 9628277 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ10 treatment (150 mg daily for 3 years)
Number of subjects: 28
Study 9628277 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ10 treatment
Number of subjects: 28
Study 9628277 — intervention group
Group type: COMPARATOR
Intervention: Control (16 MIDD patients, 5 mutant IGT, and 5 mutant NGT subjects)
Number of subjects: 28
Study 8208451 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngotracheal topical spray of lidocaine 4% (2 ml) in Group L
Number of subjects: 20
Study 8208451 — intervention group
Group type: COMPARATOR
Intervention: Saline in Group F (control)
Number of subjects: 20
Study 2530945 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (2.5 to 10 mg orally twice a day)
Number of subjects: 78
Study 2530945 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (60 to 240 mg orally twice a day)
Number of subjects: 78
Study 4578361 — intervention group
Group type: EXPERIMENTAL
Intervention: PAS plus isoniazid daily
Number of subjects: 0
Study 4578361 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptomycin plus isoniazid twice a week
Number of subjects: 0
Study 4578361 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptomycin plus isoniazid twice a week for 1 year, then once a week
Number of subjects: 0
Study 4578361 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of chemotherapy beyond 18 months
Number of subjects: 0
Study 4578361 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months sanatorium treatment
Number of subjects: 0
Study 4578361 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 months sanatorium treatment
Number of subjects: 0
Study 30739389 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pharmacist–provided services
Number of subjects: 40
Study 30739389 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care
Number of subjects: 40
Study 26786187 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (moderate intensity, 3 times per week for 16 weeks)
Number of subjects: 46
Study 26786187 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control
Number of subjects: 46
Study 26786187 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-exercise hypotension
Number of subjects: 46
Study 26021752 — intervention group
Group type: EXPERIMENTAL
Intervention: High EGFR protein expression
Number of subjects: 663
Study 26021752 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased HER4 mRNA expression
Number of subjects: 663
Study 26021752 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR protein expression
Number of subjects: 663
Study 26021752 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of high EGFR, high HER2, low HER3 and low HER4 mRNA expression
Number of subjects: 663
Study 23647408 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) for 6 weeks on acupoints Baihui (DU20) and Zusanli (ST36)
Number of subjects: 75
Study 23647408 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (20 mg/day) for 6 weeks
Number of subjects: 75
Study 23647408 — intervention group
Group type: COMPARATOR
Intervention: Electroacupuncture (EA) for 6 weeks on acupoints Taichong (LR3), Sanyinjiao (SP6), Neiguan (PC6), and Shenmen (HT7)
Number of subjects: 75
Study 21427654 — intervention group
Group type: EXPERIMENTAL
Intervention: Buflomedil 600 mg/day for six months
Number of subjects: 23
Study 21427654 — intervention group
Group type: COMPARATOR
Intervention: No medication (Control)
Number of subjects: 23
Study 19371942 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral varicocelectomy (BV)
Number of subjects: 104
Study 19371942 — intervention group
Group type: COMPARATOR
Intervention: Left varicocelectomy (LV)
Number of subjects: 104
Study 19371942 — intervention group
Group type: COMPARATOR
Intervention: Comparison of BV and LV
Number of subjects: 104
Study 17404487 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (RTX)
Number of subjects: 0
Study 17404487 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (RTX) with methotrexate
Number of subjects: 0
Study 17404487 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 15082202 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin 20mg/40ml (Group A)
Number of subjects: 622
Study 15082202 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin 30mg/40ml (Group B)
Number of subjects: 622
Study 15082202 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin 40mg/40ml (Group C)
Number of subjects: 622
Study 15082202 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin (all groups)
Number of subjects: 622
Study 11176737 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based attending physicians
Number of subjects: 4456
Study 11176737 — intervention group
Group type: COMPARATOR
Intervention: Clinic-based attending physicians
Number of subjects: 4456
Study 10437209 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood-letting puncture with cupping
Number of subjects: 45
Study 10437209 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study 1980826 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroleptic and antiparkinsonian medication
Number of subjects: 0
Study 1980826 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 7033746 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C tablets taken daily for 100 days
Number of subjects: 190
Study 7033746 — intervention group
Group type: COMPARATOR
Intervention: Placebo taken daily for 100 days
Number of subjects: 190
Study 30488144 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention addressing clinician burnout
Number of subjects: 192
Study 30488144 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention addressing clinician interactions with consumers
Number of subjects: 192
Study 30488144 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 192
Study 27256372 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 30
Study 27256372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 26424232 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified directly observed therapy
Number of subjects: 259
Study 26424232 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 259
Study 25358723 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care programme (PC programme)
Number of subjects: 182
Study 25358723 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 182
Study 22008447 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (≤ 60 mg/day) for up to 14 weeks
Number of subjects: 2850
Study 20158007 — intervention group
Group type: EXPERIMENTAL
Intervention: AR splint (Group I)
Number of subjects: 50
Study 20158007 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed orthodontic appliance (Group II)
Number of subjects: 50
Study 20158007 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control Group)
Number of subjects: 50
Study 18618513 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid
Number of subjects: 153
Study 18618513 — intervention group
Group type: COMPARATOR
Intervention: Control pamphlet
Number of subjects: 153
Study 16089275 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine (150 mg/kg L-crystalline tyrosine)
Number of subjects: 20
Study 16089275 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 12052998 — intervention group
Group type: EXPERIMENTAL
Intervention: MDT care
Number of subjects: 152
Study 12052998 — intervention group
Group type: COMPARATOR
Intervention: ICP
Number of subjects: 152
Study 10593374 — intervention group
Group type: EXPERIMENTAL
Intervention: Midluteal start of leuprolide acetate (LA) 1 mg/d, reduced to 0.5 mg/d after addition of gonadotropins (LUT)
Number of subjects: 170
Study 10593374 — intervention group
Group type: COMPARATOR
Intervention: Oral contraceptive (OC) pills until cycle day 0 followed by 20 microg of LA every 12 hours on cycle day 3 with addition of gonadotropins on cycle day 5 (MICRO)
Number of subjects: 170
Study 10593374 — intervention group
Group type: COMPARATOR
Intervention: MICRO
Number of subjects: 170
Study 10593374 — intervention group
Group type: EXPERIMENTAL
Intervention: LUT
Number of subjects: 170
Study 8970626 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 g/kg/day of IVIg for the first 5 days after transplantation
Number of subjects: 41
Study 8970626 — intervention group
Group type: COMPARATOR
Intervention: Control group (no IVIg treatment)
Number of subjects: 41
Study 8970626 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIg infusion
Number of subjects: 41
Study 1593552 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of PGF2 alpha diluted to 20 mL in normal saline
Number of subjects: 54
Study 1593552 — intervention group
Group type: COMPARATOR
Intervention: 20 mL of normal saline alone
Number of subjects: 54
Study 2932299 — intervention group
Group type: EXPERIMENTAL
Intervention: EE/NG
Number of subjects: 11
Study 2932299 — intervention group
Group type: EXPERIMENTAL
Intervention: EE/DG
Number of subjects: 11
Study 30688871 — intervention group
Group type: EXPERIMENTAL
Intervention: Back Squat (BS)
Number of subjects: 11
Study 30688871 — intervention group
Group type: EXPERIMENTAL
Intervention: Front Squat (FS)
Number of subjects: 11
Study 29348196 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone treatment
Number of subjects: 523
Study 29348196 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 523
Study 27290652 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation (450 mg/day)
Number of subjects: 64
Study 27290652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 24395136 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 27
Study 24395136 — intervention group
Group type: COMPARATOR
Intervention: Control group (poor responders)
Number of subjects: 27
Study 22878166 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 161
Study 22878166 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 161
Study 19931895 — intervention group
Group type: EXPERIMENTAL
Intervention: fesoterodine 4 mg or 8 mg once daily
Number of subjects: 883
Study 19931895 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 883
Study 19931895 — intervention group
Group type: EXPERIMENTAL
Intervention: fesoterodine
Number of subjects: 883
Study 17499425 — intervention group
Group type: EXPERIMENTAL
Intervention: hK2 and percent free PSA
Number of subjects: 91
Study 15642030 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser (ERL) using a cone‐shaped glass fiber tip at an energy setting of 100 mJ/pulse and 10 pps
Number of subjects: 20
Study 15642030 — intervention group
Group type: COMPARATOR
Intervention: Mechanical debridement using plastic curettes and antiseptic therapy with chlorhexidine digluconate (0.2%) (C)
Number of subjects: 20
Study 12065466 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg melatonin daily for 6 months
Number of subjects: 8
Study 12065466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 12065466 — intervention group
Group type: EXPERIMENTAL
Intervention: Post cessation of melatonin
Number of subjects: 8
Study 12065466 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum gonadotropin levels
Number of subjects: 8
Study 9468235 — intervention group
Group type: EXPERIMENTAL
Intervention: Emulsified diazepam
Number of subjects: 211
Study 9468235 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 211
Study 7597663 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine 5'-monophosphate (AMP)
Number of subjects: 91
Study 7597663 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise challenge
Number of subjects: 91
Study 7597663 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine
Number of subjects: 91
Study 7597663 — intervention group
Group type: EXPERIMENTAL
Intervention: AMP
Number of subjects: 91
Study 7597663 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 91
Study 2103708 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic nimodipine
Number of subjects: 58
Study 2103708 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment specified)
Number of subjects: 58
Study 760732 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpropamide suspension
Number of subjects: 0
Study 760732 — intervention group
Group type: COMPARATOR
Intervention: Chlorpropamide tablet formulations
Number of subjects: 0
Study 760732 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpropamide (all formulations)
Number of subjects: 0
Study 30836951 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided 12-week web-based intervention (Group 1; n=65)
Number of subjects: 156
Study 30836951 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized institutional rehabilitation program (Group 2; n=52)
Number of subjects: 156
Study 30836951 — intervention group
Group type: COMPARATOR
Intervention: Support provided by voluntary caregiver associations (Group 3; n=39)
Number of subjects: 156
Study 28116765 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine treatment with 600 mg/d α-lipoic acid intravenously (α-LA group)
Number of subjects: 62
Study 28116765 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (DM group)
Number of subjects: 62
Study 25537278 — intervention group
Group type: EXPERIMENTAL
Intervention: TARGET 1® (active formulation)
Number of subjects: 87
Study 25537278 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 23770108 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise (4 days/week at 60%-65% HRmax)
Number of subjects: 126
Study 23770108 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise (4 days/week at 80%-85% HRmax)
Number of subjects: 126
Study 23770108 — intervention group
Group type: COMPARATOR
Intervention: Usual care (wait-listed controls)
Number of subjects: 126
Study 21305444 — intervention group
Group type: COMPARATOR
Intervention: Control warm-up at 8.00 am
Number of subjects: 8
Study 21305444 — intervention group
Group type: COMPARATOR
Intervention: Control warm-up at 4.00 pm
Number of subjects: 8
Study 21305444 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended warm-up at 8.00 am
Number of subjects: 8
Study 21305444 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended warm-up at 4.00 pm
Number of subjects: 8
Study 19255334 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance rituximab (MR) 375 mg/m² once per week for 4 weeks every 6 months for 2 years
Number of subjects: 311
Study 19255334 — intervention group
Group type: COMPARATOR
Intervention: Observation (OBS)
Number of subjects: 311
Study 17269368 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic asthma patients
Number of subjects: 42